NGS Panel "LUNG 1" : EGFR-BRAF-MET-KRAS

Back to the list
Eurofins Biomnis code

POUM1

Synonyms
  • Companion test
  • NGS
  • oncology
  • Solid tumor
  • Targeted therapy
Specialty

Genetics


Clinical significance

The NGS "LUNG1" panel associated with the FISH unitary test fulfil the routine needs of clinicians for prescribing targeted therapies for locally advanced or metastatic NSCLC. In 2020, the EGFR (mutation), ALK (rearrangement), ROS1 (rearrangement), RET (rearrangement),BRAF (mutation), NTRK (rearrangement) and MET (mutation) status can be used to guide the selection of targeted therapy (TMA (temporary marketing authorization)). In addition, KRAS status is included in this panel.

Preanalytics
  • A tube specifically for this analysis : No
Further information

Use the specific request form B9-INTGB: Oncology-Solid tumors
The use of the S25UK transport bag is Mandatory.
Attach the anatomopathological report

Specific equipment available
  • S25 : Envelope Genetics and Molecular Oncology

Methodology

Targeted sequencing of cancer genes (NGS) : -Library : AmpliSeq Library PLUS for Illumina Custom Panel V1 - Amplicon-based targeted library preparation method -NGS Platform : MiSeq Illumina - Flowcell : microV2 (2x150pb) - Paired-end reads -Analysis software : Miseq control Software version 2.6.2.1 /SeqOne Platform v1.2 - CE Pipeline version : SomaVar v1.4 CE -Limit of detection : 5% -Minimum depth accepted : 500x -Human genome version : Hg19

Turnaround time

10 business days


Testing Laboratory

Biomnis Lyon